Biotech | November 30, 2022
Lonza collaborates with AbTis to extend Bioconjugation capabilities
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Subscribe To Our Newsletter & Stay Updated
